Drug Trial Radar · NCT07751848
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
417
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Aug 25, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to describe clinical outcomes, with focus on remission, achieved with use of anifrolumab participants with SLE on standard-of-care (as recommended by 2025 China SLE guidelines). Further, it aims to describe outcomes alongside a systematic approach to glucocorticoid (GC) tapering, in terms of effectively minimising GC use, as well as discontinuing GC use, thereby reducing GC exposure.
Conditions
- Lupus Erythematosus, Systemic
Interventions
AnifrolumabDrug
The study intervention, anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes from Week 0 to Week 48 for a total of 13 doses. Each dose must be at least 14 days apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients who achieve DORIS remission at week 52Time frame: Week 52
Locations
74 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Beijing, China · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Bengbu, China · Recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Changde, China · Not yet recruiting
Research Site
Changlexi, China · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Dalian, China · Not yet recruiting
Research Site
Fuzhou, China · Not yet recruiting
Research Site
Guangdong Province, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Hangzhou, China · Not yet recruiting
Research Site
Hangzhou, China · Not yet recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Harbin, China · Not yet recruiting
Research Site
Hefei, China · Recruiting
Research Site
Hengyang, China · Not yet recruiting
Research Site
Hohhot, China · Not yet recruiting
Research Site
Jinan, China · Not yet recruiting
Research Site
Kunming, China · Not yet recruiting
Research Site
Lanzhou, China · Recruiting
Research Site
Linyi, China · Not yet recruiting
Research Site
Luoyang, China · Recruiting
Research Site
Luzhou, China · Not yet recruiting
Research Site
Nanchang, China · Not yet recruiting
Research Site
Nanchong, China · Recruiting
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.